Rein Therapeutics closed at $0.66 on Nov 4, down 1.32%, 65.0% below its 52-week closing high. Volume of 213.9K shares was 0.51× its 20-day average (below normal).
Split-adjusted performance: -20.2% over one month, -43.7% over six months, -62.4% over one year.
Short interest was 590.8K shares at the Oct 15 settlement, down 9.3% from the prior report (2.6% of float, 1.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RNTXRein Therapeutics | $0.6587 | −1.32% | −43.7% | — | — | — | $56.8M | |
| HRTXHeron Therapeutics | $0.2986 | +4.88% | −77.2% | +1.3% | −14.6% | — | $56.7M | Compare |
| XLOXilio Therapeutics | $8.71 | +0.35% | +10.3% | +131.2% | −34.1% | — | $57.3M | Compare |
| RFLRafael Holdings | $1.07 | −0.93% | −14.4% | −30.3% | −3760.7% | — | $55.8M | Compare |
| CTORCitius Oncology | $0.5470 | −0.55% | −39.8% | — | −597.4% | — | $57.9M | Compare |
| NMADNomad Power Solutions | $3.60 | +2.27% | — | — | — | — | $58.0M | Compare |
| ONCYOncolytics Biotech | $0.4248 | +8.92% | −53.8% | — | — | — | $55.7M | Compare |
| BOLDBoundless Bio | $2.40 | +0.84% | +51.9% | — | — | — | $55.5M | Compare |
| CLNNClene | $4.10 | +8.75% | −42.7% | +233.3% | −14915.6% | — | $58.3M | Compare |
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
